Education
About Us
Working with TipRanks
Follow Us
Verastem (VSTM)
NASDAQ:VSTM
VSTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.40 - $11.25
Previous CloseN/A
Volume547.29K
Average Volume (3M)3.06M
Market Cap
$662.84M
Enterprise Value$227.65M
Total Cash (Recent Filing)$164.32M
Total Debt (Recent Filing)$75.32M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Oct 30, 2025EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding61,545,270
10 Day Avg. Volume2,892,992
30 Day Avg. Volume3,064,929
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue-29.04
Enterprise Value/Gross Profit-26.97
Enterprise Value/Ebitda-1.39
Forecast
1Y Price Target
$15.00Price Target Upside39.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Market OpportunityThe company's KRASG12D inhibitor program presents a significant market opportunity, estimated at over $1.5 billion.
Regulatory ApprovalVerastem's avutometinib plus defactinib combination received accelerated approval from the FDA for the treatment of low-grade serous ovarian cancer.
Revenue PerformanceThe launch of Avmapki Fakzynja Co-pack is going well, with revenue exceeding expectations and broad payer coverage.
Bears Say
Financial LossVerastem reported a net loss of $0.35 per diluted share, compared to consensus estimated net loss of $0.73 per share.
Safety ConcernsSafety, especially gastrointestinal signals, remains a key focus due to high rates of grade 3 or higher treatment-related adverse effects.
Verastem News
VSTM FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $2.40 and its highest was $11.24 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $662.84M.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Oct 30, 2025 which is in 53 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Aug 07, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.728 by $0.338.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.62.
How many shares outstanding does Verastem have?
Verastem has 61,545,270 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.728. Following the earnings report the stock price went up 19.929%.
Which hedge fund is a major shareholder of Verastem?
Currently, no hedge funds are holding shares in VSTM
Verastem Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (39.28% Upside)
$15.00 (39.28% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 62.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $127.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 8.3%
Last 30 Days ▼ 8.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
348.75%
12-Months-Change
Fundamentals
Return on Equity
-437.92%
Trailing 12-Months
Asset Growth
85.60%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
VSTM Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment, with significant achievements such as the early FDA approval and successful commercial launch of AVMAPKI FAKZYNJA CO-PACK. These positive developments were partially offset by increased R&D expenses and net loss. However, the highlights significantly outweigh the lowlights, indicating strong momentum and future potential.View all VSTM earnings summariesVSTM Stock 12 Month Forecast
Average Price Target
$15.00
▲(39.28% Upside)
Technical Analysis
Cardiff Oncology
―
Mereo Biopharma Group Plc
―
Monopar Therapeutics Inc
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Ownership Overview
1.40% Insiders
5.75% Mutual Funds
47.31% Other Institutional Investors
34.24% Public Companies and
Individual Investors